Top

Clinical Research in Cardiology

Published in:

01-03-2014 | Original Paper

The effect of placebo adherence on reducing cardiovascular mortality: a meta-analysis

Authors: Zhao Yue, Cheng Cai, Yang Ai-fang, Tang Feng-min, Chen Li, Wang Bin

Published in: Clinical Research in Cardiology | Issue 3/2014

Abstract

Objective

We aim to demonstrate the effect of placebo adherence on reducing CV mortality.

Backgrounds

Good adherence, whether to drug or placebo treatment, is associated with lower CV mortality. However, current evidence for the positive effect of placebo adherence on reducing CV mortality is relatively weak.

Methods

We conducted a fixed-effect meta-analysis of eight randomized clinical trials to evaluate the effect of placebo adherence on reducing CV mortality. We made a comparison between good placebo adherence and poor drug adherence.

Results

Compared with poor adherence to drug treatment, good adherence to placebo treatment was associated with lower CV mortality (OR = 0.68, 95 % CI 0.60–0.77).

Conclusion

Good adherence to placebo has a positive effect on reducing CV mortality. The effect of adherence on reducing CV mortality may be independent of the drug effect.

Available only for authorised users

Osterberg L, Blaschke T (2005) Drug therapy—adherence to medication. N Engl J Med 353:487–497PubMedCrossRef

Ho PM, Maddox TM, Shetterly SM, Rumsfeld JS, Magid DJ (2008) The costs of healthcare associated with medication non-adherence. Circulation 117:E460

Ewen S, Rettig-Ewen V, Mahfoud F, Bohm M, Laufs U (2013) Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol. doi:10.1007/s00392-013-0616-8

Herrler T, Bohm M, Heeschen C (2008) More good reasons for adherence to statin therapy during acute coronary syndromes. Eur Heart J 29:2061–2063PubMedCrossRef

Rublee DA, Chen SY, Mardekian J, Wu N, Rao P, Boulanger L (2012) Evaluation of cardiovascular morbidity associated with adherence to atorvastatin therapy. Am J Ther 19:24–32PubMedCrossRef

Rasmussen JN, Chong A, Alter DA (2007) Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 297:177–186PubMedCrossRef

Padula AM, Pressman AR, Vittinghoff E, Grady D, Neuhaus J, Ackerson L, Rudd P, Avins AL (2012) Placebo adherence and mortality in the Heart and Estrogen/Progestin Replacement Study. Am J Med 125:804–810PubMedCentralPubMedCrossRef

Pressman A, Avins AL, Neuhaus J, Ackerson L, Rudd P (2012) Adherence to placebo and mortality in the Beta Blocker Evaluation of Survival Trial (BEST). Contemp Clin Trials 33:492–498PubMedCentralPubMedCrossRef

Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA (2006) A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333:15PubMedCentralPubMedCrossRef

10.

Granger BB, Swedberg K, Ekman I, Granger CB, Olofsson B, McMurray JJ, Yusuf S, Michelson EL, Pfeffer MA (2005) Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 366:2005–2011PubMedCrossRef

11.

Irvine J, Baker B, Smith J, Jandciu S, Paquette M, Cairns J, Connolly S, Roberts R, Gent M, Dorian P (1999) Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Psychosom Med 61:566–575PubMed

12.

Shepherd JCSLR (1997) Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J 18:1718–1724CrossRef

13.

Obias-Manno D, Friedmann E, Brooks MM, Thomas SA, Haakenson C, Morris M, Wimbush F, Somelofski C, Goldner F (1996) Adherence and arrhythmic mortality in the cardiac arrhythmia suppression trial (CAST). Ann Epidemiol 6:93–101PubMedCrossRef

14.

Glynn RJ, Buring JE, Manson JE, LaMotte F, Hennekens CH (1994) Adherence to aspirin in the prevention of myocardial infarction. The Physicians’ Health Study. Arch Intern Med 154:2649–2657PubMedCrossRef

15.

Gallagher EJ, Viscoli CM, Horwitz RI (1993) The relationship of treatment adherence to the risk of death after myocardial infarction in women. JAMA 270:742–744PubMedCrossRef

16.

Horwitz RI, Viscoli CM, Berkman L, Donaldson RM, Horwitz SM, Murray CJ, Ransohoff DF, Sindelar J (1990) Treatment adherence and risk of death after a myocardial infarction. Lancet 336:542–545PubMedCrossRef

17.

Pl C (1980) Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 303:1038–1041CrossRef

18.

Fernandes JL, Serrano CV, Toledo F, Hunziker MF, Zamperini A, Teo FH, Oliveira RT, Blotta MH, Rondon MU, Negrao CE (2011) Acute and chronic effects of exercise on inflammatory markers and B-type natriuretic peptide in patients with coronary artery disease. Clin Res Cardiol 100:77–84CrossRef

19.

Walenta K, Sinning JM, Werner C, Bohm M (2011) Hotline update of clinical trials and registries presented at the at the European Society of Cardiology Congress in Paris 2011. Clin Res Cardiol 100:955–971PubMedCrossRef

20.

Andersohn F, Willich SN (2009) The healthy adherer effect. Arch Intern Med 169:1635–1636PubMedCrossRef

21.

Menckeberg TT, Bouvy ML, Bracke M, Kaptein AA, Leufkens HG, Raaijmakers J, Horne R (2008) Beliefs about medicines predict refill adherence to inhaled corticosteroids. J Psychosom Res 64:47–54PubMedCrossRef

22.

Blaschke TF, Osterberg L, Vrijens B, Urquhart J (2012) Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 52:275–301PubMedCrossRef

23.

Mancia G, Ferrari A, Gregorini L, Parati G, Pomidossi G, Bertinieri G, Grassi G, di Rienzo M, Pedotti A, Zanchetti A (1983) Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 53:96–104PubMedCrossRef

24.

Millar-Craig MW, Bishop CN, Raftery EB (1978) Circadian variation of blood-pressure. Lancet 1:795–797PubMedCrossRef

25.

Zugck C, Franke J, Gelbrich G, Frankenstein L, Scheffold T, Pankuweit S, Duengen HD, Regitz-Zagrosek V, Pieske B, Neumann T, Rauchhaus M, Angermann CE, Katus HA, Ertl GE, Stork S (2012) Implementation of pharmacotherapy guidelines in heart failure: experience from the German Competence Network Heart Failure. Clin Res Cardiol 101:263–272PubMedCrossRef

26.

Stilley CS, Sereika S, Muldoon MF, Ryan CM, Dunbar-Jacob J (2004) Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Ann Behav Med 27:117–124PubMedCrossRef

27.

Jespersen L, Abildstrom SZ, Hvelplund A, Prescott E (2013) Persistent angina: highly prevalent and associated with long-term anxiety, depression, low physical functioning, and quality of life in stable angina pectoris. Clin Res Cardiol 102:571–581PubMedCrossRef

28.

Schowalter M, Gelbrich G, Stork S, Langguth JP, Morbach C, Ertl G, Faller H, Angermann CE (2013) Generic and disease-specific health-related quality of life in patients with chronic systolic heart failure: impact of depression. Clin Res Cardiol 102:269–278PubMedCrossRef

29.

Kripalani S, Henderson LE, Jacobson TA, Vaccarino V (2008) Medication use among inner-city patients after hospital discharge: patient-reported barriers and solutions. Mayo Clin Proc 83:529–535PubMed

30.

Ayalon L (2008) Subjective cognitive functioning as a predictor of all cause mortality in an Israeli national sample of community dwelling older adults. Int J Geriatr Psychiatry 23:830–836PubMedCrossRef

31.

Rudman LA, Gonzales MH, Borgida E (1999) Mishandling the gift of life: noncompliance in renal transplant patients. J Appl Soc Psychol 29:834–851CrossRef

32.

Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J (1998) Persistence of use of lipid-lowering medications—A cross-national study. JAMA J Am Med Assoc 279:1458–1462CrossRef

33.

White HD (2005) Adherence and outcomes: it’s more than taking the pills. Lancet 366:1989–1991PubMedCrossRef

34.

Ho PM, Bryson CL, Rumsfeld JS (2009) Medication adherence: its importance in cardiovascular outcomes. Circulation 119:3028–3035PubMedCrossRef

35.

Laufs U, Rettig-Ewen V, Bohm M (2011) Strategies to improve drug adherence. Eur Heart J 32:264–268PubMedCrossRef

36.

Gitt AK, Junger C, Jannowitz C, Karmann B, Senges J, Bestehorn K (2011) Adherence of hospital-based cardiologists to lipid guidelines in patients at high risk for cardiovascular events (2L registry). Clin Res Cardiol 100:277–287PubMedCrossRef

37.

Bohm M, Schumacher H, Laufs U, Sleight P, Schmieder R, Unger T, Teo K, Yusuf S (2013) Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J 166(306–314):e7PubMed

Title: The effect of placebo adherence on reducing cardiovascular mortality: a meta-analysis
Authors: Zhao Yue
Cheng Cai
Yang Ai-fang
Tang Feng-min
Chen Li
Wang Bin
Publication date: 01-03-2014
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology / Issue 3/2014
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-013-0642-6

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The effect of placebo adherence on reducing cardiovascular mortality: a meta-analysis

Abstract

Objective

Backgrounds

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Backgrounds

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2014

Association of high-sensitivity assayed troponin I with cardiovascular phenotypes in the general population: the population-based Gutenberg health study

Effect of remote ischaemic conditioning on contrast-induced nephropathy in patients undergoing elective coronary angiography (ERICCIN): rationale and study design of a randomised single-centre, double-blind placebo-controlled trial

Impact of type 2 diabetes mellitus and glucose control on fractional flow reserve measurements in intermediate grade coronary lesions

Edwards Sapien XT valve placement as treatment option for aortic regurgitation after transfemoral CoreValve implantation: a multicenter experience

Improving care of post-infarct patients: effects of disease management programmes and care according to international guidelines

Drug adherence in patients taking oral anticoagulation therapy

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page